^
Association details:
| Biomarker: | DIRAS3 expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition
Published date:
06/02/2020
Excerpt:
In 2 human OvCa xenograft models, the DIRAS3-expressing tumors treated with crizotinib had significantly decreased tumor burden and long-term survival in 67% to 79% of mice. Crizotinib treatment of autophagic cancer cells further enhanced autophagy and induced autophagy-mediated apoptosis by decreasing phosphorylated STAT3 and BCL-2 signaling.
DOI:
10.1002/cncr.32985
